Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07406438Phase 1Not Yet Recruiting

To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Role: lead

NCT07237464Phase 1Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants

Role: lead

NCT07126288Phase 2Not Yet Recruiting

Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency

Role: lead

NCT05908071Phase 3Unknown

Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

Role: lead

NCT05676073Phase 2Completed

Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19

Role: lead

NCT05504746Phase 1Completed

A Phase I Study of SHEN26 Capsule in Healthy Participants

Role: lead

All 6 trials loaded